News 03.09.2019 Schlieren (Zurich), Switzerland, September 3, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase 2a clinical trial to evaluate the use of Fibrin-PTH (KUR-113) in...
News 27.08.2019 Research & Development: MP0250 (VEGF x HGF) in MM: PI Trial (in combination with Velcade®) – Encouraging responses observed in first patient cohorts triggered decision for further investment; IMiD Trial (in combination with Pomalyst®) – Start of phase 2 trial expected in Q4 19, having received FDA approval; MP0250 in...
External events
Event date: 19.09.2019
1-6h30 PM, Lausanne, Sept 19th 2019
Agora Centre, CHUV University Hospital
https://www.swissbiotech.org/swiss-biotech-insight-20190919/
About the event
This first in a series of Swiss Biotech Insight Events will address major clinical trial strategy challenges, while exploring exciting new solutions including real world data science, adaptive clinical trial design, biomarkers and more.
Join us to hear from top experts from throughout the...
External events
Event date: 03.10.2019
1. Digital Health Lab Day - Life in numbers 5 on Thursday, October 3, 2019 in Wädenswil.
ZHAW researchers and practitioners will present and discuss the latest trends and solutions in the field of Digital Health. The experts will also present specific tools for solving current challenges in thematic workshops.
What...
News 20.08.2019 Schlieren (Zurich), Switzerland, August 20, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today reported its results for the first half year 2019. The Company accelerated product sales in the first half of 2019, while further decreasing administrative expenses, confirming its successful transition into a full-fledged...